Elevated tissue expression of phosphorylated S6 ribosomal protein, serving as a downstream surrogate readout of the mTORC1-S6K molecular signaling axis, is independently associated with higher Ki-67 proliferation indices and malignant histological status in retroperitoneal extravisceral perivascular epithelioid cell tumors, according to a retrospective investigation conducted by researchers at Peking University and Peking University International Hospital. Pathological risk stratification for perivascular epithelioid cell neoplasms currently relies predominantly on subjective morphological evaluation, while objective immunohistochemical biomarkers capable of distinguishing malignancy and assessing recurrence risk remain sparse in clinical pathology.
To evaluate the potential diagnostic utility of quantitative immunohistochemical profiling in this rare anatomical subset, the research team retrospectively identified and enrolled 32 patients diagnosed with retroperitoneal extravisceral perivascular epithelioid cell tumors. Tumor tissue specimens obtained from the cohort underwent standardized immunohistochemical evaluation for phosphorylated S6 expression, which the investigators systematically quantified using the composite H-score scoring framework. Alongside tissue-level molecular assessments, the authors compiled comprehensive clinicopathological records and longitudinal follow-up information across all 32 enrolled individuals to evaluate correlations between molecular readouts and clinical disease features.
The statistical protocol encompassed a range of non-parametric and multivariable techniques to analyze protein expression distributions and clinicopathological variables. Bivariate relationships were initially probed through Spearman rank correlation coefficients, while differences across subgroups were tested utilizing the Mann-Whitney U test and the Kruskal-Wallis H-test combined with post-hoc Dunn-Bonferroni correction methods. To adjust for concurrent clinical factors and evaluate whether expression elevations were independent, the investigators constructed multivariable linear regression models in which histological classification categories were entered using dummy variables with benign lesions functioning as the explicit reference group. In addition, receiver operating characteristic curve analysis was conducted to assess diagnostic discrimination.
Analysis of quantitative expression data demonstrated that phosphorylated S6 H-scores maintained a moderate positive correlation with the Ki-67 cellular proliferation index (r = 0.613, P < 0.001) and an inverse moderate correlation with maximum tumor diameter (r = -0.397, P = 0.024). Stratified group comparisons revealed statistically significant variations across anatomical and histological presentations, showing higher phosphorylated S6 H-scores among non-fat-rich lesions, recurrent tumors, tumors of uncertain malignant potential, and frankly malignant cases, with each subgroup comparison reaching statistical significance at P < 0.05.
In multivariable linear regression modeling designed to isolate independent contributors to marker elevation, only the Ki-67 proliferation index and malignant histological status relative to benign histology remained independently associated with increased phosphorylated S6 H-scores. Other clinicopathological parameters evaluated within the multivariable framework—specifically uncertain malignant potential status, overall tumor size, fat-rich tissue composition, and tumor nodule pattern—failed to demonstrate any statistically significant independent association with the quantified immunohistochemical H-score.
When evaluated for its ability to discriminate malignant neoplasms from non-malignant lesions, receiver operating characteristic analysis of the phosphorylated S6 H-score yielded an area under the curve of 0.994, with a 95 percent confidence interval ranging from 0.976 to 1.000. On the basis of this diagnostic trajectory, the authors identified an H-score of 130 as an exploratory decision threshold for separating malignant lesions. However, the researchers emphasized that this quantitative threshold remains strictly exploratory and requires extensive external validation across independent patient cohorts before any consideration for direct clinical adoption.
The study also highlighted several critical limitations regarding clinical interpretation and prospective prognostic utility. Although tumor recurrence was descriptively more frequent among patients displaying higher phosphorylated S6 H-scores, the authors observed that this association is substantially confounded by the underlying histological risk category of the tumors. Furthermore, clinical observations collected from three patients treated with mTOR inhibitors represent preliminary hypothesis-generating data that cannot validate phosphorylated S6 as a predictive biomarker for therapeutic response, underscoring the necessity for further independent validation studies.
In their final evaluation, the investigators emphasized that while phosphorylated S6 exhibits higher expression in malignant retroperitoneal extravisceral perivascular epithelioid cell tumors, its immediate clinical application remains constrained. Because pathological risk stratification currently depends largely on subjective morphological assessment, objective immunohistochemical biomarkers for evaluating malignancy and recurrence risk remain limited. The authors explicitly concluded that the quantitative H-score cut-off of 130 is exploratory and not ready for direct clinical use.
Consequently, the research team noted that further independent validation is warranted to thoroughly evaluate the potential biomarker value of quantitative phosphorylated S6 immunohistochemistry in perivascular epithelioid cell tumors. As a tissue-level surrogate readout downstream of the mTORC1-S6K axis, phosphorylated S6 may offer valuable objective diagnostic insights once future studies validate its performance and clarify its broader utility in pathological risk assessment.
Subject of Research: Phospho-S6 immunohistochemical expression and clinicopathological characteristics in retroperitoneal extravisceral PEComas
Article Title: Expression of phospho-S6 and its correlation with clinicopathological characteristics in retroperitoneal extravisceral perivascular epithelioid cell tumors
Article References: Liu, L., Li, W., Liu, S., Chen, J., & Zhao, J. (2026). Expression of phospho-S6 and its correlation with clinicopathological characteristics in retroperitoneal extravisceral perivascular epithelioid cell tumors. Frontiers in Oncology, 16, Article 1969609. https://doi.org/10.3389/fonc.2026.1969609
Image Credits: AI Generated
DOI: 10.3389/fonc.2026.1969609
Keywords: retroperitoneal extravisceral PEComas, perivascular epithelioid cell tumors, phospho-S6, p-S6 immunohistochemistry, H-score system, Ki-67 proliferation index, mTORC1-S6K axis, pathological risk stratification, malignant PEComa, uncertain malignant potential, tumor diameter, ROC curve analysis, multivariable linear regression, mTOR inhibitors, tumor recurrence, retroperitoneum oncology, biomarker validation
News Source: Nathaniel Bowman. (November 17, 2026). Elevated Phospho-S6 Expression Correlates With Malignancy in Retroperitoneal Extravisceral PEComas. Scienmag.



